Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8728441 | 0.83 | SMN1; SMN2 (0.39) | DRD3DRD2NPC1RAB9ATBXA2R | |
| SCHEMBL19726336 | 0.82 | DRD2 (0.33) | DRD3DRD2TSHRKMT2A | |
| SCHEMBL28381288 | 0.79 | SLC6A4 (0.42) | TP53KMT2A | |
| SCHEMBL3725001 | 0.78 | MAPT (0.51) | NPC1RAB9A | |
| SCHEMBL6200513 | 0.78 | ALDH1A1 (0.42) | — | |
| SCHEMBL16127116 | 0.78 | PNMT (0.36) | TSHRKMT2A | |
| SCHEMBL30493157 | 0.78 | PNMT (0.42) | — | |
| SCHEMBL1197541 | 0.78 | PNMT (0.42) | — | |
| SCHEMBL1196934 | 0.76 | FABP7 (0.50) | TSHRKMT2A | |
| SCHEMBL30493000 | 0.76 | FABP7 (0.50) | TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247693-B1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2017-12-21 | — | — | US | disclosed |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | CYP3A5, SQLE, CYP3A4 | AKT1 2745/4885DRD3 539/4885DRD2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.